A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

  • End date
    Dec 21, 2023
  • participants needed
  • sponsor
    RemeGen Co., Ltd.
Updated on 21 March 2022


This study will evaluate the effectiveness and safety of intravenous injection of RC48-ADC in the treatment of HER2 expression (HER2 positive and HER2 low expression) gynecological malignancies.


This study is an open, multi-cohort, multi-center Phase II basket clinical study that included HER2 expression (HER2 positive and HER2 low expression) gynecological malignant tumor subjects. The four cohorts include cervical cancer, ovarian epithelial cancer、 fallopian tube cancer and primary peritoneal cancer, endometrial cancer and other gynecological malignancies (vulvar cancer, vaginal cancer, primary sarcoma of the gynecological reproductive system, etc.). Each cohort enrolled 30 subjects. Among them, IHC+, IHC2+, IHC3+ subjects were enrolled at least 5 subjects, and the remaining 15 subjects were not restricted by HER2 expression. HER2 expression includes HER2 positive and HER2 low expression. HER2 positive is defined by the immunohistochemical IHC 2+/fluorescence in situ hybridization technique FISH+ or IHC 3+ judged by the central laboratory. HER2 low expression is defined as IHC 2+/FISH- or IHC+ as determined by the central laboratory. The Molecular Pathology Department of the Department of Pathology, Cancer Hospital of the Chinese Academy of Medical Sciences will serve as the research center laboratory to confirm the HER2 status (including IHC and FISH tests).

Condition Gynecological Malignancy
Treatment RC48-ADC
Clinical Study IdentifierNCT04965519
SponsorRemeGen Co., Ltd.
Last Modified on21 March 2022


Yes No Not Sure

Inclusion Criteria

\. Meet all the conditions of any of the following queues
Queue one
Histologically confirmed patients with recurrent or metastatic cervical cancer who have failed at least the first-line platinum-containing standard treatment or failed concurrent radiotherapy and chemotherapy
Not suitable for surgery or radiotherapy
Queue two
Ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer confirmed histologically
The subject has previously received a standard platinum-containing chemotherapy regimen, and at the same time meets any of the following criteria
Platinum-resistant relapsed patients who have undergone at least 2 lines (can contain BRCA
mutations or HRD-positive patients who have failed PARP inhibitors) standard treatment
failure (relapse or progression time and previous platinum-containing regimen last
chemotherapy (at least 4 cycles) The interval between time is less than 6 months); or at
least three lines (patients who have failed PARP inhibitors on BRCA mutations or
HRD-positive patients) platinum-sensitive relapsed patients who have failed standard
treatment (the time to relapse or progression is related to The interval between the last
platinum-containing chemotherapy (at least 4 cycles) is ≥ 6 months); Note: The definition
of recurrence or progression (meet any of the following conditions): a) There is clearly
recorded imaging progress; b) CA-125 continues to rise (CA-125 ≥ 2 times the upper limit of
normal, and it needs to be confirmed after 1 week ) With clinical symptoms or physical
examination suggesting disease progression
Queue three
Patients who have failed the standard treatment of at least first-line
Recurrent or metastatic endometrial cancer confirmed histologically
platinum-containing chemotherapy
Not suitable for surgery or radiotherapy
Queue four
Recurrent or metastatic other gynecological malignancies (vulvar cancer, vaginal
cancer, primary sarcoma of the gynecological reproductive system, etc.) that have
Not suitable for surgery or radiotherapy
failed standard treatments confirmed by histology
Voluntarily agree to participate in the research and sign an informed consent form
Female, age ≥18 years old
Expected survival period ≥ 12 weeks
The central laboratory confirms the expression of HER2: IHC 1+, 2+ or 3+; the
subject can provide specimens of the primary or metastatic tumor site for HER2
detection (paraffin blocks, paraffin-embedded sections or fresh tissue sections are
acceptable); IHC2+ Of subjects need to be tested for FISH. Note: The scoring standard
for HER2 testing is determined by the central laboratory
With measurable lesions specified by RECIST 1.1 standard
ECOG physical status 0 or 1 point
Sufficient organ functions should meet the following criteria during the screening
period (the normal value is subject to the clinical trial center): Left ventricular
ejection fraction ≥50%; Hemoglobin ≥9g/dL; Absolute neutrophil count (ANC)≥1.5×109/L
Platelets ≥100 ×109/L; Serum total bilirubin ≤ 1.5 times the upper limit of normal
(ULN); ALT and AST≤2.5 × ULN when there is no liver metastasis, and ALT and AST≤5 ×
ULN when there is liver metastasis; Serum creatinine≤1.5×ULN or calculate creatinine
clearance rate (CrCl)≥50 mL/min according to Cockcroft-Gault formula method
Female subjects should be surgically sterilized, post-menopausal patients, or agree
to use at least one medically approved contraceptive method (such as intrauterine
contraceptive devices, contraceptives, or condom).The blood pregnancy test must be
negative within 7 days before study entry, and it must be a non-lactating period
Willing and able to follow the trial and follow-up procedures

Exclusion Criteria

Suffering from central nervous system metastasis and/or cancerous meningitis
Subjects who have received brain metastasis therapy may consider participating in this
study, provided that the condition is stable for at least 3 months, no disease
progression has been confirmed by imaging examination within 4 weeks before the first
dose of the study, and all neurological symptoms have recovered At baseline, there is
no evidence of new or enlarged brain metastases, and radiation, surgery, or steroid
therapy should be discontinued at least 28 days before the first dose of study
treatment. This exception does not include cancerous meningitis, which should be
excluded regardless of whether the clinical condition is stable or not
The toxicity caused by previous anti-tumor treatments has not been restored to
CTCAE (version 5.0) 0-1 grade (except for 2nd degree alopecia)
Major surgery has been performed within 4 weeks before the start of study
administration and has not fully recovered
A large amount of pleural fluid or ascites accompanied by clinical symptoms or
requiring symptomatic treatment
Serum virology examination (subject to the normal value of the research center): The
HBsAg test result is positive, and the HBV DNA copy number is positive at the same
time; HCVAb test result is positive (only if the PCR test result of HCV RNA is
negative, it can be selected for this study); HIVAb test result is positive
Have received live vaccines within 4 weeks before the start of the study
administration or plan to receive any vaccines during the study period (except the new
crown vaccination)
Heart failure classified by the New York College of Cardiology (NYHA) as grade 3
and above
Severe arterial/venous thrombotic events or cardiovascular and cerebrovascular
accidents occurred within 1 year before the study administration, such as deep vein
thrombosis (not including asymptomatic intermuscular vein thrombosis without special
treatment), pulmonary embolism, cerebral infarction, Cerebral hemorrhage, myocardial
infarction, etc., except for lacunar infarction that is asymptomatic and does not
require clinical intervention
There are active or advanced infections that require systemic treatment, such as
active tuberculosis
There are systemic diseases that have not been stably controlled by researchers
including diabetes, hypertension, liver cirrhosis, interstitial pneumonia, obstructive
pulmonary disease, etc
There are active autoimmune diseases requiring systemic treatment (such as
immunomodulatory drugs, corticosteroids or immunosuppressive agents) within 2 years
before the start of study administration, and related alternative treatments (such as
thyroxine, insulin, or renal or Physiological corticosteroid replacement therapy for
pituitary insufficiency)
Suffered from other malignant tumors within 5 years before the start of study
administration, except for the following conditions: Malignant tumors that can be
expected to heal after treatment (including but not limited to fully treated thyroid
cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal
carcinoma in situ treated by radical surgery)
Have previously received allogeneic hematopoietic stem cell transplantation
Have received other antibody-conjugated drug therapy in the past
Those who are known to be allergic to recombinant humanized anti-HER2 monoclonal
antibody-MMAE coupling agent drugs and their components
Suffer from any other diseases, metabolic abnormalities, abnormal physical
examinations or abnormal laboratory examinations. According to the judgment of the
investigator, there is reason to suspect that the patient has a certain disease or
condition that is not suitable for the use of the study drug, or will affect the
interpretation of the study results , Or put the patient in a high-risk situation
It is estimated that the compliance of patients to participate in this clinical
study is insufficient
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note